Medicare Plans’ Preferential Coverage For Off-Label Drugs Debated
Executive Summary
A debate is brewing over how Medicare should handle plans' step-therapy practices that encourage beneficiaries to try an off-label treatment before coverage is granted for a drug with an FDA-approved indication
You may also be interested in...
Cost Effectiveness Decisions Playing Greater Role In Off-Label Coverage
The role of cost analysis in the context of comparative effectiveness research has been hotly contested, but cost effectiveness is already gaining importance as a factor in how third-party payers run Medicare and Medicaid prescription drug plans
Cost Effectiveness Decisions Playing Greater Role In Off-Label Coverage
The role of cost analysis in the context of comparative effectiveness research has been hotly contested, but cost effectiveness is already gaining importance as a factor in how third-party payers run Medicare and Medicaid prescription drug plans
Part D Formulary Edits: CMS Focus On Covering All Labeled Uses Unwarranted, PCMA Says
Pharmacy benefit managers express alarm that CMS is shifting on its definition of a medically-accepted indication for Medicare drug coverage.